[HTML] frontiersin.org

[HTML][HTML] The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

E Moorkens, B Godman, I Huys, I Hoxha… - Frontiers in …, 2021 - frontiersin.org
Background: From October 2018, adalimumab biosimilars could enter the European market.
However, in some countries, such as Netherlands, high discounts reported for the originator …
被引用次数：69 相关文章
[HTML] frontiersin.org

[HTML][HTML] The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

E Moorkens, B Godman, I Huys, I Hoxha… - Frontiers in …, 2021 - frontiersin.org
Background: From October 2018, adalimumab biosimilars could enter the European market.
However, in some countries, such as Netherlands, high discounts reported for the originator …

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

E Moorkens, B Godman, I Huys, I Hoxha, A Malaj… - 2021 - fhi.brage.unit.no
Background: From October 2018, adalimumab biosimilars could enter the European market.
However, in some countries, such as Netherlands, high discounts reported for the originator …

Market exclusivity and the entry of adalimumab biosimilars in Europe: an overview of pricing and national policy measures

E Moorkens, B Godman, I Huys, I Hoxha, A Malaj… - 2021 - um.edu.mt
Background: From October 2018, adalimumab biosimilars could enter the European market.
However, in some countries, such as Netherlands, high discounts reported for the originator …

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

E Moorkens, B Godman, I Huys… - Frontiers in …, 2021 - unirepository.svkri.uniri.hr
Background: From October 2018, adalimumab biosimilars could enter the European market.
However, in some countries, such as Netherlands, high discounts reported for the originator …

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

E Moorkens, B Godman, I Huys, I Hoxha… - Frontiers in …, 2021 - dabar.srce.hr
Abstract (english) From October 2018, adalimumab biosimilars could enter the European
market. However, in some countries, such as Netherlands, high discounts reported for the …

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures.

E Moorkens, B Godman, I Huys, I Hoxha… - Frontiers in …, 2020 - europepmc.org
Background: From October 2018, adalimumab biosimilars could enter the European market.
However, in some countries, such as Netherlands, high discounts reported for the originator …

[引用][C] The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

E Moorkens, I Huys, AG Vulto, B Godman… - Frontiers in …, 2020 - elibrary.ru

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

E Moorkens, B Godman, I Huys… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Background: From October 2018, adalimumab biosimilars could enter the European market.
However, in some countries, such as Netherlands, high discounts reported for the originator …

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

E Moorkens, B Godman, I Huys, I Hoxha… - Frontiers in …, 2021 - purerims.smu.ac.za
Background: From October 2018, adalimumab biosimilars could enter the European market.
However, in some countries, such as Netherlands, high discounts reported for the originator …